Optimizing Management of Chronic GVHD: The Care Team’s Role in Symptom Management and Patient Care : Episode 5
Patient Communication and Collaborative Care for Symptom Management
Panelists discuss how physician assistants educate and empower chronic graft-versus-host disease patients and their caregivers to recognize, report, and manage symptoms effectively, detailing strategies for patient communication, developing personalized symptom management plans, addressing challenging symptoms, and collaborating with the broader healthcare team to ensure comprehensive care.
EP: 1.Chronic Graft-versus-Host Disease: Understanding the Disease and Its Widespread Symptoms
EP: 2.Comprehensive Patient Education and Symptom Awareness with GVHD
EP: 3.Managing Severe Symptoms and Disease Progression in the GVHD Journey
EP: 4.Early Symptom Detection and the Impact on Patient Outcomes in GVHD
Now Viewing
EP: 5.Patient Communication and Collaborative Care for Symptom Management
Video content above is prompted by the following:
- As a PA, what strategies do you use to help patients recognize and report their symptoms effectively?
- How do you counsel patients and caregivers on identifying, managing, and communicating (to who: e.g. nurse navigator, pharmacists, patient portal) these symptoms with their healthcare team?
- Please provide an example or 2 of what that patient conversation looks like.
- Can you walk us through your process for developing and adjusting symptom management plans for cGVHD patients? How do you involve patients in this process?
- What are some of the most challenging symptoms to manage in cGVHD patients, and how do you approach these challenges?
- How do you collaborate with other members of the healthcare team to ensure comprehensive symptom management for cGVHD patients?
Recent Videos
Related Content
BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD
August 11th 2024Article
The biologics license application that was resubmitted for remestemcel-L has been accepted by the FDA for the potential treatment of children with steroid-refractory acute graft-vs-host-disease.
